BioCryst Pharmaceuticals, Inc.
HealthcareNASDAQ:BCRX · NASDAQ Global Select
+$0.20 today
Vol 2.39M · Avg 5.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-221.4%
avg 73.6%
ROIC
93.9%
avg -36.4%
ROA
51.3%
avg -36.9%
Analysis
ROIC is currently the strongest return metric at 93.9% versus its period average of -36.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Charles K. Gayer | CEO, President & Director | $1.38M | — | 55 | $952,583.00 | 0.45% |
Alane Barnes | Senior Vice President, Chief Legal Officer & Corporate Secretary | $1.11M | — | 60 | $400,703.00 | 0.19% |
Babar Ghias | Chief Financial Officer & Head of Corporate Development | $948,415.00 | — | 47 | $355,050.00 | 0.17% |
William Sheridan MBBS | Chief Development Officer | $784,089.00 | — | 71 | $39,354.00 | 0.02% |
Yarlagadda S. Babu | Chief Discovery Officer | $691,450.00 | — | 73 | $298,541.00 | 0.14% |
John Ruesch | Chief Technical Operations Officer | — | — | — | — | — |
Philip George | Chief Strategy Officer | — | — | — | $49,933.00 | 0.02% |
Jinky Ang Rosselli | Chief Data Innovation Officer | — | — | — | — | — |
Stephanie Angelini | Chief People Officer & Chief Communications Officer | — | — | — | — | — |
Nick Wilder | Manager of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$4.73M
Net Sentiment
$4.73M
Net selling
Most Active
Barnes Alane P
7 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $4.73M over the last 12 months. That adds up to net selling of $4.73M. Barnes Alane P was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +22.4% | +24.2% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.4% over three years. Forward estimates point to Revenue at +24.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.86B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Upstream Bio, Inc.
UPB
$331.96M
Who manages BCRX?
BioCryst Pharmaceuticals, Inc. (BCRX) lists 10 active executives. The top listed executive is Babar Ghias, Chief Financial Officer & Head of Corporate Development.
Are BCRX insiders buying or selling?
Recent insider activity shows net buying of $38.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.